TY - JOUR
T1 - Stereotactic radiosurgery as adjuvant or salvage treatment for sporadic hemangioblastomas
T2 - A multi-center international study
AU - Tos, Salem M.
AU - Maroufi, S. Farzad
AU - Hajikarimloo, Bardia
AU - Shaaban, Ahmed
AU - Mantziaris, Georgios
AU - Pham, Duy
AU - Dayawansa, Sam
AU - Nabeel, Ahmed M.
AU - Reda, Wael A.
AU - Tawadros, Sameh R.
AU - AbdelKarim, Khaled
AU - El-Shehaby, Amr M.N.
AU - Emad, Reem M.
AU - Wei, Zhishuo
AU - McKendrick, Lindsay M.
AU - Niranjan, Ajay
AU - Lunsford, L. Dade
AU - Peker, Selcuk
AU - Samanci, Yavuz
AU - Liscak, Roman
AU - May, Jaromir
AU - Mathieu, David
AU - Lee, Cheng chia
AU - Yang, Huai che
AU - Dono, Antonio
AU - Blanco, Angel I.
AU - Esquenazi, Yoshua
AU - Moreno, Nuria Martinez
AU - Álvarez, Roberto Martinez
AU - Picozzi, Piero
AU - Franzini, Andrea
AU - Tripathi, Manjul
AU - Sumi, Takuma
AU - Uzuka, Takeo
AU - Kano, Hideyuki
AU - Bailey, David
AU - Zacharia, Brad E.
AU - Cifarelli, Christopher P.
AU - Cifarelli, Daniel T.
AU - Hack, Joshua D.
AU - Speckter, Herwin
AU - Lazo, Erwin
AU - Warnick, Ronald E.
AU - Schoenhals, Jonathan E.
AU - Palmer, Joshua D.
AU - Ishaque, Mariam
AU - Asthagiri, Ashok
AU - Xu, Zhiyuan
AU - Sheehan, Jason P.
N1 - Publisher Copyright:
© 2025 Elsevier B.V.
PY - 2025/12/15
Y1 - 2025/12/15
N2 - Introduction: Hemangioblastomas are rare benign CNS tumors, occurring sporadically or with von Hippel-Lindau disease. While surgical resection is the primary treatment, GKRS serves as an adjuvant or salvage option when resection is not feasible. This study evaluates long-term outcomes of GKRS in patients with sporadic hemangioblastomas. Methods: We retrospectively analyzed 82 patients with sporadic hemangioblastomas treated with GKRS across 17 International Radiosurgery Research Foundation centers (1993–2022). Univariate and multivariate analysis was conducted to identify variables influencing local control and tumor regression. Results: Among 82 patients (52.4 % male, median age 51.5 years [IQR: 40.3–63.0]), most tumors were cerebellar (70.7 %), solid (63.4 %), with a median volume of 1.8 cc [IQR: 0.8–6.1]. The median margin dose was 16.0 Gy [IQR: 14.0–18.0]. With a median follow-up of 51.5 months [IQR: 21.0–92.0], local control was achieved in 69.5 % of cases (40.2 % regression, 29.3 % stability). Local control rates were 95 % (90 %, 100 %) at 6 months but declined to 75 % (65 %, 87 %) at 60 months. Radiation necrosis occurred in 6.1 % of patients (5/82), and no tumor-related deaths were reported among the 11.1 % overall mortality. Brainstem location was significantly linked to lower odds of tumor regression in the multivariate analysis (OR: 0.29, 95 % CI: 0.09–0.98, p = 0.045). Conclusion: GKRS demonstrated efficacy and safety in treating sporadic hemangioblastomas, achieving reasonable long-term local control rates with minimal complications. Our findings support its role as a viable treatment option, particularly for surgically challenging cases.
AB - Introduction: Hemangioblastomas are rare benign CNS tumors, occurring sporadically or with von Hippel-Lindau disease. While surgical resection is the primary treatment, GKRS serves as an adjuvant or salvage option when resection is not feasible. This study evaluates long-term outcomes of GKRS in patients with sporadic hemangioblastomas. Methods: We retrospectively analyzed 82 patients with sporadic hemangioblastomas treated with GKRS across 17 International Radiosurgery Research Foundation centers (1993–2022). Univariate and multivariate analysis was conducted to identify variables influencing local control and tumor regression. Results: Among 82 patients (52.4 % male, median age 51.5 years [IQR: 40.3–63.0]), most tumors were cerebellar (70.7 %), solid (63.4 %), with a median volume of 1.8 cc [IQR: 0.8–6.1]. The median margin dose was 16.0 Gy [IQR: 14.0–18.0]. With a median follow-up of 51.5 months [IQR: 21.0–92.0], local control was achieved in 69.5 % of cases (40.2 % regression, 29.3 % stability). Local control rates were 95 % (90 %, 100 %) at 6 months but declined to 75 % (65 %, 87 %) at 60 months. Radiation necrosis occurred in 6.1 % of patients (5/82), and no tumor-related deaths were reported among the 11.1 % overall mortality. Brainstem location was significantly linked to lower odds of tumor regression in the multivariate analysis (OR: 0.29, 95 % CI: 0.09–0.98, p = 0.045). Conclusion: GKRS demonstrated efficacy and safety in treating sporadic hemangioblastomas, achieving reasonable long-term local control rates with minimal complications. Our findings support its role as a viable treatment option, particularly for surgically challenging cases.
UR - https://www.scopus.com/pages/publications/105021849210
UR - https://www.scopus.com/pages/publications/105021849210#tab=citedBy
U2 - 10.1016/j.jns.2025.125656
DO - 10.1016/j.jns.2025.125656
M3 - Article
C2 - 41242005
AN - SCOPUS:105021849210
SN - 0022-510X
VL - 479
JO - Journal of the neurological sciences
JF - Journal of the neurological sciences
M1 - 125656
ER -